Manmeet Soni - May 5, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role: COO, CFO and President
Signature: /s/ Tracy Herson, attorney-in-fact
Stock symbol: RETA
Transactions as of: May 5, 2023
Transactions value $: $0
Form type: 4
Date filed: 5/9/2023, 04:35 PM
Previous filing: Mar 8, 2023
Next filing: May 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$0	+50K	+56.62%	$0.00	138K	May 5, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Employee Stock Option (right-to-buy)	Award	$0	+50K		$0.00	50K	May 5, 2023	Class B common stock	50K	$104.79	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 29, 2019, the reporting person was granted 50,000 Restricted Stock Units subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the 50,000 RSUs vested.
F2	On August 29, 2019, the reporting person was granted an option to purchase 50,000 shares of Class B common stock subject to performance criteria. On May 5, 2023, based on the satisfaction of certain performance criteria, the option vested as to 50,000 shares.